On September 18, 2023, an optimistic development emerged for BioCryst Pharma (NASDAQ:BCRX) as RBC Capital analyst Brian Abrahams upgraded the company’s status from Sector Perform to Outperform. Additionally, the price target for BioCryst Pharma’s stock was raised from $9 to $10. These positive changes in rating and price target indicate that RBC Capital holds a more favorable perspective on BioCryst Pharma’s stock performance and believes it possesses the potential to surpass market expectations.
BioCryst Pharmaceuticals, Inc.
BCRX
Neutral
Updated on: 03/12/2023
Weak 
DCF: Strong Buy 
BCRX Stock Shows Mixed Performance with Positive Earnings and Revenue Growth
BCRX stock had a mixed performance on September 18, 2023. The stock opened at $6.94, slightly higher than the previous day’s close of $6.92. Throughout the day, the stock traded in a range between $6.72 and $6.94. The volume for the day was 5,206,464 shares, which is significantly higher than the average volume of 2,530,646 shares over the past three months. The market cap for BCRX is $1.3 billion.
In terms of earnings growth, BCRX had a decline of 29.35% last year. However, this year, the company has shown positive growth with a 28.23% increase. Looking ahead, analysts expect BCRX to continue its growth trajectory with a projected earnings growth of 39.51% over the next five years. This positive outlook is supported by the company’s revenue growth of 72.31% in the past year.
BCRX’s price-to-earnings (P/E) ratio is not available (NM), indicating that the company may not have positive earnings. However, the price-to-sales ratio is 7.88, suggesting that the stock may be relatively expensive compared to its sales.
In terms of other stocks in the health technology sector, Iovance Biotherapeutics (IOVA) saw a positive change of 13.46% on September 18, while Arvinas Inc (ARVN) experienced a decline of 3.40%. ANI Pharmaceuticals (ANIP) and Aurinia Pharmaceuticals (AUPH) also had negative changes of 1.92% and 2.64% respectively.
BCRX is a biotechnology company headquartered in Durham, North Carolina. It operates in the health technology sector and has a focus on developing innovative therapies. The company does not have any executives listed.
Overall, BCRX stock had a mixed performance on September 18, 2023. The company has shown positive earnings and revenue growth, which may contribute to its positive outlook for the future. Investors should keep an eye on BCRX as it continues to navigate the biotechnology industry.
BioCryst Pharmaceuticals Inc (BCRX) Stock Shows Positive Performance and Potential Increase of 67.88%: Analysts Consensus Buy Rating
On September 18, 2023, BioCryst Pharmaceuticals Inc (BCRX) saw a positive performance in its stock. According to data from CNN Money, the 10 analysts who provided 12-month price forecasts for BCRX had a median target of 11.50, with a high estimate of 30.00 and a low estimate of 8.00. This indicates a potential increase of 67.88% from the last recorded price of 6.85.
The consensus among 11 polled investment analysts is to buy stock in BioCryst Pharmaceuticals Inc. This rating has remained steady since August.
It is worth noting that the current quarter’s earnings per share for BioCryst Pharmaceuticals Inc is reported to be -$0.23, indicating a loss. However, the company’s sales for the same period are reported to be $85.5 million.
Investors will be eagerly awaiting the reporting date of November 08, when BioCryst Pharmaceuticals Inc will release its financial results for the current quarter.
Overall, based on the positive price forecasts and the consensus buy rating from investment analysts, BioCryst Pharmaceuticals Inc appears to be an attractive investment opportunity. However, investors should closely monitor the company’s financial results and any developments in the pharmaceutical industry that may impact its performance.
Discussion about this post